A
Albiruni Ryan Abdul Razak
Researcher at Princess Margaret Cancer Centre
Publications - 253
Citations - 7154
Albiruni Ryan Abdul Razak is an academic researcher from Princess Margaret Cancer Centre. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 39, co-authored 195 publications receiving 5045 citations. Previous affiliations of Albiruni Ryan Abdul Razak include Harvard University & University Health Network.
Papers
More filters
Journal ArticleDOI
The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma.
Brian A. Van Tine,Kristen N. Ganjoo,Jean-Yves Blay,Claudia Valverde,Dejka M. Araujo,Albiruni Ryan Abdul Razak,Axel Le Cesne,Scott M. Schuetze,Michael R. Wagner,Steven Attia,Edouard Forcade,Mihaela Druta,Seth M. Pollack,J. Bai,Paige Bayer,Erin Van Winkle,Elliot Norry,Cheryl McAlpine,Dennis Williams,Sandra P. D'Angelo +19 more
TL;DR: The SPEARHEAD-1 (NCT04044768) trial as mentioned in this paper reported interim overall survival (OS) data in the pts with advanced synovial sarcoma in Cohort 1.
Journal ArticleDOI
Early circulating tumor DNA (ctDNA) kinetics using a tumor-naïve assay as a predictive biomarker in early-phase immunotherapy (IO) clinical trials.
Enrique Sanz Garcia,Sofia Genta,Xiaoxi Chen,Qiuxiang Ou,Daniel Vilarim Araujo,Albiruni Ryan Abdul Razak,Aaron R. Hansen,Anna Spreafico,Hua Bao,Xue Wu,Lillian L. Siu,Philippe L. Bedard +11 more
TL;DR: In a pan-cancer solid tumor early phase trial IO phase I/II trials, a decrease in ctDNA within 4 weeks of treatment was associated with CB, OS did not show greater increases, and no differences in mean VAF change were seen between HPD and PD pts.
Journal ArticleDOI
475P Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase I update
Hans Gelderblom,Albiruni Ryan Abdul Razak,Javier Martin-Broto,Breelyn A. Wilky,Piotr Rutkowski,Sandeep Narasimhan,Melissa Vallee,M. C. Sharma,Rodrigo Ruiz-Soto,Matthew L. Sherman,William D. Tap +10 more
TL;DR: Vimseltinib as discussed by the authors is an oral switch-control tyrosine kinase inhibitor specifically designed to selectively and potently inhibit CSF1R, which is a rare, locally aggressive neoplasm caused by upregulation of the colony-stimulating factor 1 (CSF1) gene.
Journal ArticleDOI
Synergistic activity of PARP inhibitors (PARPi) in combination with standard chemotherapy (CTx) in leiomyosarcoma.
Olga Vornicova,Yael Babichev,Rima Al-awar,Richard C. Marcellus,Albiruni Ryan Abdul Razak,Rebecca A. Gladdy +5 more
TL;DR: Most synergistic combination in the majority of LMS cell lines were Dox or Tmz when combined with Tala, reaching up to 15 % and 27% above Bliss respectively, which suggest that such approach may be extended to all sites of L MS.
Journal ArticleDOI
Patient-Reported Outcomes and Tolerability in Patients Receiving Ripretinib versus Sunitinib After Treatment with Imatinib in INTRIGUE, a Phase 3, Open-Label Study
Hans Gelderblom,Jean-Yves Blay,Suzanne George,Margaret von Mehren,John Zalcberg,Yoon-Koo Kang,Albiruni Ryan Abdul Razak,Jonathan C. Trent,Steven Attia,Axel Le Cesne,B Siontis,David Goldstein,Kjetil Boye,Neeltje Steeghs,Piotr Rutkowski,Mihaela Druta,César Serrano,Neeta Somaiah,Ping Chi,Brooke S. Harrow,Claus Becker,William M. Reichmann,Matthew L. Sherman,Rodrigo Ruiz-Soto,Michael Heinrich,Sebastian Bauer +25 more